指南与共识心血管外周血管CT

关于使用计算机断层扫描血管造影对非钙化斑块和高危斑块及其他生物标志物进行客观分析验证的QIBA共识轮廓特别报告

Special Report on the Consensus QIBA Profile for Objective Analytical Validation of Non-calcified and High-risk Plaque and Other Biomarkers using Computed Tomography Angiography.
指南 / 共识 · Acad Radiol · 2024-07-26

该报告由定量影像生物标志物联盟(QIBA)制定,旨在提高无创斑块表型分析的客观性并减少变异性。轮廓对单个斑块形态测量(偏倚、斜率、变异性)及多参数斑块稳定表型(与专家病理学家的一致性)提出声明,适用于研究发现、临床试验和患者诊疗。

要点

  • 轮廓分别评估单个斑块形态测量的偏倚(准确性)、斜率(偏倚在测量范围内的稳定性)和变异性。
  • 多参数斑块稳定表型通过其与专家病理学家判读结果的一致性来评估。
  • 轮廓旨在为研究发现、临床试验和患者诊疗提供客观验证分析性能的方法。

核心结论

  • 本报告提供轮廓声明的理由和概述,以及如何在研究和临床实践中遵循轮廓。

研究设计与样本

  • 由定量影像生物标志物联盟(QIBA)制定的共识轮廓,未报告样本量、中心数或参考标准。

诊断标准与关键数值

  • 单个斑块形态测量按偏倚(准确性)、斜率(偏倚在测量范围内的稳定性,用于测量变化)和变异性评估。
  • 多参数斑块稳定表型按与专家病理学家判读结果的一致性评估。

临床应用与阅片要点

  • 轮廓旨在为研究发现、临床试验和患者诊疗提供客观验证分析性能的方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Evidence is building in support of the clinical utility of atherosclerotic plaque imaging by computed tomography angiography (CTA). There is increasing organized activity to embrace non-calcified plaque (NCP) as a formally defined biomarker for clinical trials, and high-risk plaque (HRP) for clinical care, as the most relevant measures for the field to advance and worthy of community efforts to validate. Yet the ability to assess the quantitative performance of any given specific solution to make these measurements or classifications is not available. Vendors use differing definitions, assessment metrics, and validation data sets to describe their offerings without clinician users having the capability to make objective assessments of accuracy and precision and how this affects diagnostic confidence.

MATERIALS AND METHODS: The QIBA Profile for Atherosclerosis Biomarkers by CTA was created by the Quantitative Imaging Biomarkers Alliance (QIBA) to improve objectivity and decrease the variability of noninvasive plaque phenotyping. The Profile provides claims on the accuracy and precision of plaque measures individually and when combined.

RESULTS: Individual plaque morphology measurements are evaluated in terms of bias (accuracy), slope (consistency of the bias across the measurement range, needed for measurements of change), and variability. The multiparametric plaque stability phenotype is evaluated in terms of agreement with expert pathologists. The Profile is intended for a broad audience, including those engaged in discovery science, clinical trials, and patient care.

CONCLUSION: This report provides a rationale and overview of the Profile claims and how to comply with the Profile in research and clinical practice.

SUMMARY STATEMENT: This article summarizes objective means to validate the analytical performance of non-calcified plaque (NCP), other emerging plaque morphology measurements, and multiparametric histology-defined high-risk plaque (HRP), as outlined in the QIBA Profile for Atherosclerosis Biomarkers by CTA.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Buckler AJ, Abbara S, Budoff MJ, et al. Special Report on the Consensus QIBA Profile for Objective Analytical Validation of Non-calcified and High-risk Plaque and Other Biomarkers using Computed Tomography Angiography. Acad Radiol. 2024. PMID: 39060206. doi:10.1016/j.acra.2024.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。